Medicine

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

U.S. Food and Drug Administration, Center for Drug Evaluation and Research

FDA Drug Safety Podcasts

Episodes

FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia

FDA D.I.S.C.O.: L-glutamine for sickle cell disease
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: L-glutamine for sickle cell disease

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur
2017-09-23 00:48:51 UTC
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur

FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia

FDA D.I.S.C.O.: L-glutamine for sickle cell disease
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: L-glutamine for sickle cell disease

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur
2017-10-07 15:17:52 UTC
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur

FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia

FDA D.I.S.C.O.: L-glutamine for sickle cell disease
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: L-glutamine for sickle cell disease

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur
2017-12-18 04:46:43 UTC
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur